RNA interference-mediated in vivo silencing of Fas ligand as a strategy for the enhancement of DNA vaccine potency

Human Gene Therapy

Volumn 19, Issue 8, 2008, Pages 763-773

  Huang, Bruce ^a   Mao, Chih Ping ^a   Peng, Shiwen ^a   Hung, Chien Fu ^a   Wu, T C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; DNA ENCODING SHRNA TARGETING FAS LIGAND; DNA ENCODING SHRNA TARGETING LUCIFERASE; DNA VACCINE; FAS LIGAND; LUCIFERASE; LUCIFERASE DNA; PROTEIN E7; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VIRUS DNA;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER IMMUNIZATION; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; GENE GUN IMMUNIZATION; GENE SILENCING; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; RNA INTERFERENCE;

ANIMALS; BIOLISTICS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMAGING, THREE-DIMENSIONAL; LUCIFERASES, FIREFLY; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SPLEEN; TRANSFECTION; VACCINES, DNA;

HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

EID: 50649094013     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.059     Document Type: Article

References (26)

1. Caplen, N.J. (2004). Gene therapy progress and prospects. Downregulating gene expression: The impact of RNA interference. Gene Ther. 11, 1241-1248.
2. Chen, C.H., Ji, H., Suh, K.W., Choti, M.A., Pardoll, D.M., and Wu, T.C. (1999). Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther. 6, 1972-1981.
3. Chen, C.H., Wang, T.L., Hung, C.F., Yang, Y., Young, R.A., Pardoll, D.M., and Wu, T.C. (2000). Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60, 1035-1042.
4. Donnelly, J.J., Ulmer, J.B., Shiver, J.W., and Liu, M.A. (1997). DNA vaccines. Annu. Rev. Immunol. 15, 617-648.
5. Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C., and Amigorena, S. (2002). Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20, 621-667.
6. Gurunathan, S., Klinman, D.M., and Seder, R.A. (2000). DNA vaccines: Immunology, application, and optimization. Annu. Rev. Immunol. 18, 927-974.
7. Huang, B., Mao, C.P., Peng, S., He, L., Hung, C.F., and Wu, T.C. (2007). Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine 25, 7824-7831.
8. Hung, C.F., Tsai, Y.C., He, L., Coukos, G., Fodor, I., Qin, L., Levitsky, H., and Wu, T.C. (2007a). Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther. 14, 20-29.
9. + T-cell immune responses and enhances vaccine potency. Mol. Ther. 15, 1211-1219.
10. Ji, H., Chang, E.Y., Lin, K.Y., Kurman, R.J., Pardoll, D.M., and Wu, T.C. (1998). Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int. J. Cancer 78, 41-45.
11. Kim, T.W., Hung, C.F., Ling, M., Juang, J., He, L., Hardwick, J.M., Kumar, S., and Wu, T.C. (2003). Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J. Clin. Invest. 112, 109-117.
12. Kim, T.W., Hung, C.F., Boyd, D.A., He, L., Lin, C.T., Kaiserman, D., Bird, P.I., and Wu, T.C. (2004). Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res. 64, 400-405.
13. Kim, T.W., Lee, J.H., He, L., Boyd, D.A., Hardwick, J.M., Hung, C.F., and Wu, T.C. (2005). Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res. 65, 309-316.
14. Kubo, M., Hanada, T., and Yoshimura, A. (2003). Suppressors of cytokine signaling and immunity. Nat. Immunol. 4, 1169-1176.
15. Lee, J.R., Dalton, R.R., Messina, J.L., Sharma, M.D., Smith, D.M., Burgess, R.E., Mazzella, F., Antonia, S.J., Mellor, A.L., and Munn, D.H. (2003). Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab. Invest. 83, 1457-1466.
16. Leung, R.K., and Whittaker, P.A. (2005). RNA interference: From gene silencing to gene-specific therapeutics. Pharmacol. Ther. 107, 222-239.
17. Lin, K.Y., Guarnieri, F.G., Staveley-O'Carroll, K.F., Levitsky, H.I., August, J.T., Pardoll, D.M., and Wu, T.C. (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21-26.
18. Lu, L., Qian, S., Hershberger, P.A., Rudert, W.A., Lynch, D.H., and Thomson, A.W. (1997). Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J. Immunol. 158, 5676-5684.
19. Mao, C.P., Hung, C.F., and Wu, T.C. (2007). Immunotherapeutic strategies employing RNA interference technology for the control of cancers. J. Biomed. Sci. 14, 15-29.
20. Munn, D.H., Sharma, M.D., Lee, J.R., Jhaver, K.G., Johnson, T.S., Keskin, D.B., Marshall, B., Chandler, P., Antonia, S.J., Burgess, R., Slingluff, C.L., Jr., and Mellor, A.L. (2002). Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297, 1867-1870.
21. Munn, D.H., Sharma, M.D., Hou, D., Baban, B., Lee, J.R., Antonia, S.J., Messina, J.L., Chandler, P., Koni, P.A., and Mellor, A.L. (2004). Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280-290.
22. Rescigno, M., Piguet, V., Valzasina, B., Lens, S., Zubler, R., French, L., Kindler, V., Tschopp, J., and Ricciardi-Castagnoli, P. (2000). Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1β, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: A new role for Fas ligand in inflammatory responses. J. Exp. Med. 192, 1661-1668.
23. Shankar, P., Manjunath, N., and Lieberman, J. (2005). The prospect of silencing disease using RNA interference. JAMA 293, 1367-1373.
24. Shen, L., Evel-Kabler, K., Strube, R., and Chen, S.Y. (2004). Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 22, 1546-1553.
25. Yang, R., Yang, X., Zhang, Z., Zhang, Y., Wang, S., Cai, Z., Jia, Y., Ma, Y., Zheng, C., Lu, Y., Roden, R., and Chen, Y. (2006). Single-walled carbon nanotubes-mediated in vivo and in vitro delivery of siRNA into antigen-presenting cells. Gene Ther. 13, 1714-1723.
26. Zhou, H., Zhang, D., Wang, Y., Dai, M., Zhang, L., Liu, W., Liu, D., Tan, H., and Huang, Z. (2006). Induction of CML28-specific cytotoxic T cell responses using co-transfected dendritic cells with CML28 DNA vaccine and SOCS1 small interfering RNA expression vector. Biochem. Biophys. Res. Commun. 347, 200-207.